María Pilar Civeira Murillo-rekin lankidetzan egindako argitalpenak (53)

2014

  1. Characterization of the CD40L/Oncostatin M/Oncostatin M receptor axis as an antiviral and immunostimulatory system disrupted in chronic HCV infection

    Journal of Hepatology, Vol. 60, Núm. 3, pp. 482-489

  2. Dysregulation of interferon regulatory factors impairs the expression of immunostimulatory molecules in hepatitis C virus genotype 1-infected hepatocytes

    Gut, Vol. 63, Núm. 4, pp. 665-673

2007

  1. HCV structural proteins interfere with interferon-alpha Jak/STAT signalling pathway

    Antiviral Research, Vol. 76, Núm. 2, pp. 194-197

  2. Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection

    Journal of Virology, Vol. 81, Núm. 7, pp. 3662-3666

2006

  1. Recombinant Adenoviral Vectors Turn on the Type I Interferon System without Inhibition of Transgene Expression and Viral Replication

    Molecular Therapy, Vol. 14, Núm. 1, pp. 129-138

2005

  1. Hepatitis C virus infection of primary tupaia hepatocytes leads to selection of quasispecies variants, induction of interferon-stimulated genes and NF-κB nuclear translocation

    Journal of General Virology, Vol. 86, Núm. 11, pp. 3065-3074

2004

  1. IFN-α5 mediates stronger Tyk2-stat-dependent activation and higher expression of 2′,5′-oligoadenylate synthetase than IFN-α2 in liver cells

    Journal of Interferon and Cytokine Research, Vol. 24, Núm. 8, pp. 497-503

2002

  1. Genotype mixtures of hepatitis B virus in patients treated with interferon

    Journal of Infectious Diseases, Vol. 186, Núm. 6, pp. 752-759

2001

  1. Nuclear factor-kB in the liver of patients with chronic hepatitis C: Decreased RelA expression is associated with enhanced fibrosis progression

    Hepatology, Vol. 34, Núm. 5, pp. 1041-1048

2000

  1. Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology

    Gut, Vol. 47, Núm. 3, pp. 429-435

1999

  1. Antioxidant status and glutathione metabolism in peripheral blood mononuclear cells from patients with chronic hepatitis C

    Journal of Hepatology, Vol. 31, Núm. 5, pp. 808-814

  2. Early predictors of response to treatment in patients with chronic hepatitis C

    Journal of Hepatology, Supplement

  3. Immunogenicity of variable regions of hepatitis C virus proteins: Selection and modification of peptide epitopes to assess hepatitis C virus genotypes by ELISA

    Journal of General Virology, Vol. 80, Núm. 3, pp. 727-738

1998

  1. Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C

    Hepatology, Vol. 28, Núm. 3, pp. 815-822

  2. Superoxide dismutase in patients with chronic hepatitis C virus infection

    Free Radical Biology and Medicine, Vol. 24, Núm. 7-8, pp. 1235-1241

  3. Transmission of hepatitis C virus infection to tree shrews

    Virology, Vol. 244, Núm. 2, pp. 513-520

1996

  1. Anticardiolipin antibodies in chronic hepatitis C: Implication of hepatitis C virus as the cause of the antiphospholipid syndrome

    Hepatology, Vol. 23, Núm. 2, pp. 199-204

  2. Epidemiological, clinical and therapeutic associations of hepatitis C types in western European patients

    Journal of Hepatology, Vol. 24, Núm. 5, pp. 517-524

  3. Further insights on the inhibition of HIV type 1 infection in vitro by CD4-modified synthetic peptides containing phenylalanine

    AIDS Research and Human Retroviruses, Vol. 12, Núm. 11, pp. 1023-1030

  4. Production of interleukin-2 in response to synthetic peptides from hepatitis C virus E1 protein in patients with chronic hepatitis C: Relationship with the response to interferon treatment

    Journal of Hepatology, Vol. 25, Núm. 1, pp. 1-9